Opinion of the Transparency Council – netupitant + palonosetron
At its meeting on 17 March 2025, the Transparency Council adopted opinion No. 48/2025 on the reimbursement of medicines containing the active substances netupitant + palonosetron for indications, dosages or administration methods other than those specified in the Summary of Product Characteristics, i.e. early or delayed vomiting in adults associated with highly emetogenic chemotherapy with the use of an anthracycline antibiotic and cyclophosphamide – prophylaxis